Share chart KemPharm, Inc.
Extended chart
Simple chart
About
KemPharm, Inc., специализированная фармацевтическая компания, обнаруживает и разрабатывает различные запатентованные пролекарства для лечения серьезных заболеваний в США. Компания использует свою технологию терапии с активированным лигандом для создания улучшенных пролекарственных версий одобренных FDA лекарств, а также для создания пролекарственных версий существующих соединений, которые могут найти применение при новых показаниях к заболеваниям.
More details| P/S | 0.947 |
|---|---|
| P/BV | -0.4848 |
| EV/EBITDA | -1.94 |
| EBITDA | -0.0492 |
| Число акций ао | 0.03449 млрд |
| Цена ао | 4.97 |
| Сайт | https://kempharm.com |
| P/E | 14.58 |
| Выручка | 0.0128 |
| Див.доход ао | 0 |
| ISIN | US4884452065 |
| Валюта | usd |
| IPO date | 2015-04-16 |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Валюта отчета | usd |
| Change price per day: | 0% (4.97) |
|---|---|
| Change price per week: | 0% (4.97) |
| Change price per month: | 0% (4.97) |
| Change price per 3 month: | 0% (4.97) |
| Change price per half year: | 0% (4.97) |
| Change price per year: | 0% (4.97) |
| Change price per 3 year: | -43.33% (8.77) |
| Change price per 5 year: | -61.89% (13.04) |
| Change price per year to date: | 0% (4.97) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Vanguard Group, Inc. (The) | 1380638 | 32 |
| Blackrock Inc. | 847611 | 19.64 |
| HealthInvest Partners AB | 750000 | 17.38 |
| Laurion Capital Management, LP | 571200 | 13.24 |
| Janney Montgomery Scott LLC | 494030 | 11.45 |
| Geode Capital Management, LLC | 304652 | 7.06 |
| Retirement Planning Co of New England, Inc. | 297384 | 6.89 |
| Sabby Management, LLC | 248592 | 5.76 |
| Mystic Asset Management, Inc. | 175883 | 4.08 |
| Millennium Management LLC | 165303 | 3.83 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| Credit Suisse S&P MLP Index ETN | 8.32 | 63.82 | |
| ProShares Hedge Replication ETF | 0.00199 | 6.8665973306333 | 1.47892 |
| ProShares UltraPro Russell2000 | 0.00733 | 125.96465921385 | 1.47873 |
| Vanguard Russell 3000 ETF | 0 | 38.467141890837 | 1.43817 |
| Vanguard Russell 2000 Growth ETF | 0.01 | 46.764050831914 | 0.60264 |
| Vanguard Russell 2000 ETF | 0.01 | 41.410408042578 | 1.48801 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Richard W. Pascoe | Exec. Chairman | 515.43k | 1964 (60 years) |
| Dr. Travis C. Mickle Ph.D. | Co-Founder, Pres, CEO & Director | 773.13k | 1973 (51 year) |
| Mr. R. LaDuane Clifton CPA | CFO, Sec. & Treasurer | 476.28k | 1972 (52 years) |
| Dr. Sven Guenther | Exec. VP of R&D | 497.26k | 1972 (52 years) |
| Mr. Timothy J. Sangiovanni CPA | VP & Corp. Controller | N/A | 1984 (40 years) |
| Dr. Andrew Barrett | VP of Scientific Affairs | N/A | |
| Ms. Christal M. M. Mickle M.A. | Co-Founder and Sr. VP of Operations & Product Devel. | N/A | 1979 (45 years) |
| Ms. Nichol L. Ochsner | VP of Investor Relations & Corp. Communications | N/A |
Address: United States, Celebration. FL, 1180 Celebration Boulevard - open in Google maps, open in Yandex maps
Website: https://kempharm.com
Website: https://kempharm.com
